Opiant Pharmaceuticals Inc represents a strong commitment to advancing public health through innovative pharmaceutical solutions. The company focuses on developing treatments for life-threatening addictions and drug overdoses. With a dedication to research and development, Opiant strives to improve patient outcomes and address critical medical needs. Through partnerships and collaborations with healthcare professionals, Opiant aims to provide effective and safe interventions for addiction-related disorders. By leveraging its expertise in the field, Opiant Pharmaceuticals Inc remains dedicated to making a positive impact on the lives of individuals struggling with substance abuse.

Opiant Pharmaceuticals Inc is primarily present in the United States.

Opiant Pharmaceuticals Inc has achieved significant milestones throughout its history. One of the major accomplishments includes the development and FDA approval of NARCAN Nasal Spray, a life-saving medication used to reverse opioid overdose. The company has also made strides in the treatment of opioid use disorder with the development of nalmefene, a potential opioid antagonist therapy. Opiant Pharmaceuticals Inc continues to innovate and invest in research and development to address the growing opioid epidemic and improve patient outcomes. Through their dedication and focus, Opiant Pharmaceuticals Inc remains at the forefront of creating effective solutions for opioid-related medical emergencies.

Opiant Pharmaceuticals Inc is a pharmaceutical company specializing in the development of treatments for addiction and overdose. Founded in 2005, Opiant has focused on addressing the opioid crisis through research and innovation. The company has a strong background in opioid antagonist technology, working on advanced formulations of naloxone, a life-saving medication used to reverse opioid overdoses. Opiant Pharmaceuticals Inc has partnered with government agencies, non-profit organizations, and industry leaders to develop and commercialize opioid overdose treatments. With a commitment to saving lives and improving public health, Opiant Pharmaceuticals Inc continues to play a crucial role in combating the opioid epidemic.

The main competitors of Opiant Pharmaceuticals Inc in the market include Emergent BioSolutions Inc, Adapt Pharma Inc, and Kaleo, Inc.

Opiant Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Opiant Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing medications for treating addictions and drug overdose emergencies. Their business model revolves around the research, development, and commercialization of innovative therapeutic solutions. Opiant focuses on addressing the opioid crisis through the development of opioid antagonists, rescue medications, and other treatment options. By leveraging their expertise in addiction medicine, Opiant aims to provide effective solutions for patients, healthcare providers, and first responders. With a strong commitment to improving public health, Opiant Pharmaceuticals Inc. works diligently to develop and deliver advanced pharmaceutical products that combat addiction and save lives.

Hệ số P/E của Opiant Pharmaceuticals là 15,58.

Chỉ số P/S của Opiant Pharmaceuticals là 1,56.

Chỉ số chất lượng AlleAktien của Opiant Pharmaceuticals là 2/10.

Doanh thu của kỳ vọng Opiant Pharmaceuticals là 78,18 tr.đ. USD.

Lợi nhuận kỳ vọng Opiant Pharmaceuticals là 7,85 tr.đ. USD.

Opiant Pharmaceuticals Inc. is a leading biotechnology company in the USA specializing in the development and commercialization of drugs for drug abuse and addiction. The company aims to find innovative solutions to challenges arising from drug abuse and addiction through its various divisions. The first division of Opiant Pharmaceuticals focuses on opioid addiction therapy. The company has concentrated on the development of naloxone nasal spray, which is used to treat opioid overdoses. This product is easy to use and has already saved many lives. The second division focuses on the treatment of alcohol addiction. The company has developed a medication called OPNT003, also known as Nalmefene, which reduces cravings and desire for alcohol and helps patients overcome their addiction. It is the only medication of its kind approved in the USA. The third division of Opiant Pharmaceuticals is dedicated to the treatment of bulimia and binge-eating disorders. Here, the company has developed a medication called OPNT002, which reduces appetite and slows down carbohydrate metabolism. The medication has proven effective and will soon be submitted for approval. The fourth and final division of Opiant Pharmaceuticals is the development of medications for the treatment of narcolepsy and other sleep-wake cycle disorders. The company has developed various medications aimed at reducing the symptoms of these disorders and normalizing the sleep-wake cycle. Based on these examples, it is evident that Opiant Pharmaceuticals focuses on the development of medications aimed at treating physical dependencies and disorders. The company's goals are comprehensively covered through its various divisions. Opiant Pharmaceuticals' business model is based on the development and commercialization of innovative solutions for the treatment of addictions and disorders. The company works closely with regulatory authorities and medical institutions to test the products and obtain approval. Once the products are approved, they are marketed and sold by Opiant Pharmaceuticals. To successfully implement the business model, Opiant Pharmaceuticals has built a team of experts who work closely with the various divisions of the company. The company's management has a high level of experience in the pharmaceutical industry and has an extensive network of contacts and partners. In summary, Opiant Pharmaceuticals has an innovative business model aimed at helping people overcome their addictions and disorders. Through the development and commercialization of effective medications, the company continues to be at the forefront of the pharmaceutical industry.

Opiant Pharmaceuticals cổ tức hàng năm là 0 USD, được phân phối qua lần thanh toán trong năm.

Hiện tại không thể tính toán được cổ tức cho Opiant Pharmaceuticals hoặc công ty không chi trả cổ tức.

Mã ISIN của Opiant Pharmaceuticals là US6837501039.

Mã WKN của Opiant Pharmaceuticals là A2AFQ6.

Mã chứng khoán của Opiant Pharmaceuticals là OPNT.

Trong vòng 12 tháng qua, Opiant Pharmaceuticals đã trả cổ tức là . Điều này tương đương với lợi suất cổ tức khoảng . Dự kiến trong 12 tháng tới, Opiant Pharmaceuticals sẽ trả cổ tức là 0 USD.

Lợi suất cổ tức của Opiant Pharmaceuticals hiện nay là .

Opiant Pharmaceuticals trả cổ tức hàng quý. Số tiền này được phân phối vào các tháng .

Opiant Pharmaceuticals đã thanh toán cổ tức hàng năm trong 0 năm qua.

Trong 12 tháng tới, người ta kỳ vọng cổ tức sẽ đạt 0 USD. Điều này tương đương với tỷ suất cổ tức là 0 %.

Opiant Pharmaceuticals được phân loại vào ngành 'Sức khỏe'.

Để nhận được cổ tức cuối cùng của Opiant Pharmaceuticals vào ngày 25/9/2024 với số tiền 0 USD, bạn phải có cổ phiếu trong tài khoản trước ngày không hưởng quyền vào 25/9/2024.

Việc thanh toán cổ tức cuối cùng đã được thực hiện vào 25/9/2024.

Vào năm 2023, Opiant Pharmaceuticals đã phân phối 0 USD dưới hình thức cổ tức.

Cổ tức của Opiant Pharmaceuticals được phân phối bằng USD.